Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06465810 · ClinicalTrials.gov registry record
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
A clinical trial of Transthyretin Amyloidosis and ATTR-CM, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 1,850
- Enrollment target
- 20
- Study locations
NCT06465810 is a study of Transthyretin Amyloidosis and ATTR-CM that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,850 participants, above the 1,027-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06465810, a study of Transthyretin Amyloidosis and ATTR-CM, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 1,850 participants
- Enrollment target
- 20
- Study locations
Study Summary
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Conditions Studied
Interventions
- DRUG Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
- Research Site - San Francisco
Massachusetts
- Research Site - Boston
- Research Site - Boston
- Research Site - Boston
New York
- Research Site - Manhasset
- Research Site - New York
- Research Site - New York
Missouri
- Research Site - Kansas City
- Research Site - St Louis
Connecticut
- Research Site - New Haven
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,850 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2031-12-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06465810
The ClinicalTrials.gov registry entry for NCT06465810 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,850 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,027-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (80% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Transthyretin Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Treatment of transthyretin (ATTR) amyloidosis in observational study setting is the first listed.
NCT06465810 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06465810 about?
NCT06465810 is a clinical study titled "Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis". The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, inclu...
What is the current status of trial NCT06465810?
This trial is currently recruiting. The enrollment target is 1,850 participants. The study started on 2024-06-25. Estimated completion is 2031-12-29.
What conditions does trial NCT06465810 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed.
What interventions are being tested in trial NCT06465810?
The interventions under investigation include: Treatment of transthyretin (ATTR) amyloidosis in observational study setting (DRUG).
Who is sponsoring clinical trial NCT06465810?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06465810 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
RECRUITING · NA
-
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
ACTIVE NOT RECRUITING · Early Phase 1
-
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
COMPLETED
-
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.